Orchard Therapeutics plc (ORTX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Hubert Baburaj Gaspar	Chief Executive Officer, Member of Scientific Advisory Board & Executive Director	901,425	1963
Frank E. Thomas	President & Chief Operating Officer	763,953	1969
Benjamin Navon	Director of Corporation Communications	0	N/A
Fulvio Mavilio	Chief Scientific Officer	0	N/A
Robin Kenselaar	Senior Vice President & GM of EMEA Commercial Operations	0	N/A
Renee T. Leck	Head of Investor Relations	0	N/A
Leslie Meltzer	Chief Medical Officer	0	N/A
Nicoletta Loggia	Chief Technical Officer	0	N/A
Braden Parker	Chief Commercial Officer	0	N/A
John Cerio	Chief Human Resource Officer	0	N/A

Name

Title

Pay

Year Born

Hubert Baburaj Gaspar

Chief Executive Officer, Member of Scientific Advisory Board & Executive Director

901,425

1963

Frank E. Thomas

President & Chief Operating Officer

763,953

1969

Benjamin Navon

Director of Corporation Communications

N/A

Fulvio Mavilio

Chief Scientific Officer

N/A

Robin Kenselaar

Senior Vice President & GM of EMEA Commercial Operations

N/A

Renee T. Leck

Head of Investor Relations

N/A

Leslie Meltzer

Chief Medical Officer

N/A

Nicoletta Loggia

Chief Technical Officer

N/A

Braden Parker

Chief Commercial Officer

N/A

John Cerio

Chief Human Resource Officer

N/A

Description

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.